Double-blind RCTs on Magnesium Bisglycinate NMDA/GABA receptor modulation and nocturnal cortisol reduction, antidepressant remission meta-analyses, SAMe augmentation trials, and optical smartwatch HRV validation studies. Explore 674 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
CONCLUSION: This meta-analysis identified several risk factors associated with AGA presence and progression, including a family history of AGA, smoking, alcohol consumption, insufficient or poor-quality sleep,...
Pain and anxiety outcomes following cryotherapy did not differ significantly from those of the topical anesthetic agents, while treatment compliance was higher, suggesting that cryotherapy may be a promising non-pharmacological option, pending confirmation in non-inferiority trials. ClinicalTrials.gov NCT07198022.
Our results showed that higher doses and more frequent IVIG/fSCIG 10% administration were associated with a lower mean probability of increased adjusted INCAT score (i.e., lower probability of relapse), remaining < 50% in all...
Further long-term, large-scale studies are recommended to confirm this evidence.
This research is expected to provide "time-specific" evidence for exercise prescription to maximize the neurocognitive benefits and mitigate dementia risk in this population. Chinese Clinical Trial Registry: [http://www.chictr.org.cn], identifier [ChiCTR2300073737].
This study suggests that lumateperone can be considered an effective and safe adjuvant treatment for MDD.
Preliminary findings suggest that the mental health benefits of chronic RET were independent of placebo effects, notwithstanding the potential limitations of small sample size and the non-mode-specific measure of expectations.
Early itch relief with ivarmacitinib showed significant improvements in QoL, sleep, and work productivity in patients with moderate-to-severe AD.
In patients with COMISA, the combination of eszopiclone with BBTI resulted in comparable improvement in sleep quality of life to that achieved with BBTI-only therapy.
AD symptom improvement was maintained up to Week 200 with baricitinib 4 mg.
Conclusions: These findings suggest that self-compassion may play a critical role in the therapeutic effects of MDMA-AT.
Venlafaxine ER has a favorable benefit-risk profile in adult Japanese patients with GAD, indicating its potential to improve GAD symptoms as well as patients' function and exert superior anxiolytic effects over placebo without...
These results confirm the effectiveness of eptinezumab in Japanese participants with CM to reduce the burden of migraine and improve the ability to undertake daily life activities.
An updated framework specific to GAD is therefore needed to clarify the underlying cognitive mechanisms underlying this condition.
Analysis of CSF collected prospectively in a large cohort of children treated for ALL demonstrated significant changes in markers of oxidative stress and neurodegeneration within three.
Available evidence is insufficient to establish a definitive association between OSA and SCD.
Tirzepatide was effective in full symptom relief of obstructive sleep apnea syndrome and metabolic dysfunction-associated steatohepatitis.
Results indicate that in addition to objective outcomes of improved AHI, hypoxic burden associated with OSA, and heart and blood vessel risk factors, people with OSA reported benefits in symptoms, functioning, and HRQoL...
Conclusions: These post hoc analyses, based on data collected independently pre-randomization, suggest that esmethadone may be an effective adjunctive treatment for patients with AT.
Participant ratings of the usability of and satisfaction with this series of personalized N-of-1 trials of melatonin for sleep suggest these trials are both feasible and acceptable.
Vasomotor symptoms associated with menopause negatively impacted daily life, particularly sleep, among participants unsuited to hormone therapy.
Our results suggest that 12 weeks of exercise or metformin intervention may promote remyelination in PBT survivors in brain regions involved in memory and executive function, and there may be differences in the brain regions...
The results for sertraline confirm the assay sensitivity of the trial.
However, DHA dose did not affect infant HR, nor did it affect infant performance in the gap-overlap attention task.
The best model without tau PET used pTau217, clinical, and MRI data (R 2 = 0.32; area under the receiver operating characteristic curve (AUROC) for classifying a 0.5-point PACC decline = 78.6%).
In patients with MDD and moderate-to-severe anhedonia, adjunctive cariprazine improved symptoms of general depression and anhedonia, suggesting a potential benefit for patients with this clinically significant symptom.
Wb-BDNF reflects the total blood BDNF pool and avoids platelet aggregation-related confounds seen in s-BDNF measures.
This meta-analysis demonstrated that MADs effectively reduced AHI severity and increased min SpO2 in OSA patients.
Using patient-reported PHQ-9 scoring to evaluate ESCAPE-TRD results, esketamine NS produced superior short- and long-term efficacy vs.
These analyses establish how tolerization presents clinically and suggest a staged therapeutic approach: (1) tolerance induction, (2) diet liberalization, and (3) gradual dose adjustment.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
